Treatment of Pulmonary Complications in Microscopic Polyangiitis (MPO-ANCA-Associated Vasculitis)
For pulmonary complications in microscopic polyangiitis, initiate remission induction with rituximab or cyclophosphamide plus glucocorticoids (or avacopan as glucocorticoid-sparing alternative), and add plasma exchange specifically for diffuse alveolar hemorrhage with hypoxemia. 1
Remission Induction for Pulmonary Involvement
Primary Treatment Options
The 2024 KDIGO guidelines establish two equally effective first-line regimens for pulmonary complications in MPA 1:
Option 1: Rituximab-based regimen
- Rituximab combined with either:
- Glucocorticoid taper, OR
- Avacopan (C5a receptor inhibitor as glucocorticoid-sparing agent)
Option 2: Cyclophosphamide-based regimen
- Cyclophosphamide (intravenous or oral) combined with either:
- Glucocorticoid taper, OR
- Avacopan
Option 3: Combination approach
- Rituximab + 2 intravenous pulses of cyclophosphamide + glucocorticoid taper (particularly for severe disease with serum creatinine >4 mg/dl) 1
Glucocorticoid Dosing
When using glucocorticoids, start with prednisolone 1 mg/kg/day (or equivalent), maintain for 1 month, then taper to ≤15 mg/day by 3 months, and continue tapering to 5-7.5 mg/day for maintenance 2. Intravenous methylprednisolone pulses can be added when rapid effect is needed 2.
Specific Management of Diffuse Alveolar Hemorrhage
For diffuse alveolar hemorrhage with hypoxemia, plasma exchange should be considered in addition to standard immunosuppression 1. This represents a critical modification to the base regimen, as pulmonary hemorrhage affects 10% of AAV patients and significantly increases mortality risk 1.
The 2016 EULAR/ERA-EDTA guidelines support this approach, recommending plasma exchange for severe diffuse alveolar hemorrhage 3. However, the evidence quality is moderate, and plasma exchange increases serious infection risk by approximately 2.7-8.5% depending on baseline risk 4.
Common Pitfall
Do not delay plasma exchange while waiting for definitive diagnosis in patients with life-threatening alveolar hemorrhage. The mortality benefit outweighs infection risks in this specific scenario.
Interstitial Lung Disease Considerations
MPA frequently presents with interstitial lung disease (ILD), which requires distinct consideration 5, 6, 7:
- ILD often precedes MPA diagnosis in 56.76% of cases and may represent preexisting comorbidity rather than acute vasculitis manifestation 7
- Usual interstitial pneumonia (UIP) pattern on HRCT is common and associated with worse prognosis comparable to idiopathic pulmonary fibrosis 8
- Treatment approach must balance anti-inflammatory and anti-fibrotic needs 6
For MPA-ILD, standard immunosuppression with glucocorticoids and cyclophosphamide or rituximab remains first-line 7. Emerging evidence suggests antifibrotic agents (nintedanib, pirfenidone) may have a role in progressive fibrotic ILD, though this is not yet guideline-endorsed 9, 6.
Critical Decision Point
Determine whether inflammation or fibrosis dominates the clinical picture:
- Inflammatory-predominant: Acute presentation, ground-glass opacities, elevated inflammatory markers → aggressive immunosuppression
- Fibrotic-predominant: Chronic course, UIP pattern, honeycombing → consider antifibrotic agents alongside immunosuppression (though evidence is limited)
Maintenance Therapy (After Achieving Remission)
Following successful induction (typically 3-6 months), transition to maintenance therapy for 18 months to 4 years 1:
Preferred: Rituximab maintenance
- MAINRITSAN protocol: 500 mg × 2 at remission, then 500 mg at months 6,12, and 18, OR
- RITAZAREM protocol: 1000 mg after induction, then at months 4,8,12, and 16 1
Alternative: Azathioprine
- 1.5-2 mg/kg/day for 18-24 months, then reduce to 1 mg/kg/day until 4 years, then taper by 25 mg every 3 months 1
Other alternatives: Mycophenolate mofetil (2000 mg/day) or methotrexate (if GFR >60 ml/min/1.73 m²) 1
Rituximab is superior to azathioprine for preventing relapses and was associated with better quality of life outcomes in the MAINRITSAN study 1. Continue low-dose glucocorticoids (5-7.5 mg/day) for 2 years during maintenance, then slowly reduce 1.
Important Exception
In MPO-ANCA patients with renal-limited disease on dialysis and no extrarenal manifestations (including thorough chest CT evaluation), the relapse risk is low enough that maintenance therapy risks may outweigh benefits 1. However, patients with pulmonary involvement should receive standard maintenance therapy.
Refractory or Relapsing Disease
For disease unresponsive to initial therapy or relapse 1:
- Switch from cyclophosphamide to rituximab, or vice versa
- Increase glucocorticoids (intravenous or oral)
- Consider plasma exchange for refractory cases
- Relapsing disease should be reinduced with rituximab preferentially 1
Monitoring and Prophylaxis
Essential supportive measures:
- Pneumocystis jiroveci prophylaxis: Trimethoprim/sulfamethoxazole (800/160 mg alternate days or 400/80 mg daily) for all patients receiving cyclophosphamide or rituximab 2
- Monitor immunoglobulin levels every 6 months with rituximab due to hypogammaglobulinemia risk 3, 10
- Osteoporosis prophylaxis per local guidelines for all patients on glucocorticoids 2
Prognostic Factors
Worse outcomes in MPA with pulmonary involvement are associated with 7:
- Elevated serum creatinine (HR 4.08-4.95)
- Acute exacerbations of ILD (HR 4.55)
- UIP pattern on HRCT versus alternative patterns 5
Better outcomes are associated with: